Recent advances in ASOs, such as tofersen (SOD1-ALS) and BIIB105 (C9orf72-ALS), highlight the critical role of genetic biomarkers in patient stratification (Xie et al., 2025). Here, SOD1 is linked to amyotrophic lateral sclerosis.